Tango Therapeutics (TNGX) Competitors

$22.64 -2.88 (-11.27%)

As of 01:59 PM Eastern

TNGX vs. AXSM, ELAN, RDY, ARWR, and ABVX

Should you buy Tango Therapeutics stock or one of its competitors? MarketBeat compares Tango Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tango Therapeutics include Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Tango Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Axsome Therapeutics has a net margin of -26.59% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -50.30% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Tango Therapeutics	-151.15%	-50.30%	-36.25%

Axsome Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics currently has a consensus target price of $251.26, indicating a potential upside of 7.80%. Tango Therapeutics has a consensus target price of $25.00, indicating a potential upside of 10.45%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Tango Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$708.24M	16.94	-$183.17M	-$3.73	N/A
Tango Therapeutics	$62.38M	52.34	-$101.59M	-$0.87	N/A

In the previous week, Axsome Therapeutics had 1 more articles in the media than Tango Therapeutics. MarketBeat recorded 8 mentions for Axsome Therapeutics and 7 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.86 beat Axsome Therapeutics' score of -0.03 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Tango Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Elanco Animal Health?

Tango Therapeutics (NASDAQ:TNGX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Tango Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	52.34	-$101.59M	-$0.87	N/A
Elanco Animal Health	$4.72B	2.30	-$232M	-$0.50	N/A

Tango Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Tango Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 10.45%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 29.86%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Elanco Animal Health had 8 more articles in the media than Tango Therapeutics. MarketBeat recorded 15 mentions for Elanco Animal Health and 7 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.86 beat Elanco Animal Health's score of 0.41 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has a net margin of -4.95% compared to Tango Therapeutics' net margin of -151.15%. Elanco Animal Health's return on equity of 7.42% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Tango Therapeutics (NASDAQ:TNGX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Tango Therapeutics' net margin of -151.15%. Dr. Reddy's Laboratories' return on equity of 12.28% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
Dr. Reddy's Laboratories	12.90%	12.28%	8.25%

Tango Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	52.34	-$101.59M	-$0.87	N/A
Dr. Reddy's Laboratories	$3.58B	3.14	$663M	$0.77	17.49

Tango Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 10.45%. Dr. Reddy's Laboratories has a consensus target price of $16.90, indicating a potential upside of 25.50%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tango Therapeutics had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 7 mentions for Tango Therapeutics and 6 mentions for Dr. Reddy's Laboratories. Tango Therapeutics' average media sentiment score of 0.86 beat Dr. Reddy's Laboratories' score of -0.47 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tango Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Tango Therapeutics (NASDAQ:TNGX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -50.30% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Tango Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	52.34	-$101.59M	-$0.87	N/A
Arrowhead Pharmaceuticals	$829.45M	13.54	-$1.63M	-$2.15	N/A

Tango Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 10.45%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 10.15%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Arrowhead Pharmaceuticals had 22 more articles in the media than Tango Therapeutics. MarketBeat recorded 29 mentions for Arrowhead Pharmaceuticals and 7 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.86 beat Arrowhead Pharmaceuticals' score of 0.81 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Tango Therapeutics beats Arrowhead Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Abivax?

Tango Therapeutics (NASDAQ:TNGX) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Tango Therapeutics and Tango Therapeutics both had 7 articles in the media. Abivax's average media sentiment score of 1.14 beat Tango Therapeutics' score of 0.86 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -50.30% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
Abivax	N/A	-146.43%	-88.69%

Tango Therapeutics has higher revenue and earnings than Abivax. Tango Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	52.34	-$101.59M	-$0.87	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tango Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 10.45%. Abivax has a consensus target price of $137.15, suggesting a potential upside of 13.83%. Given Abivax's stronger consensus rating and higher possible upside, analysts plainly believe Abivax is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Tango Therapeutics beats Abivax on 8 of the 15 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.26B	$3.40B	$6.30B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-25.96	18.73	20.92	25.65
Price / Sales	52.34	294.61	551.58	76.73
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	8.81	6.77	9.87	6.72
Net Income	-$101.59M	$24.11M	$3.55B	$333.73M
7 Day Performance	-3.60%	0.05%	-0.20%	0.40%
1 Month Performance	-5.88%	0.91%	1.48%	4.09%
1 Year Performance	1,661.48%	77.69%	41.00%	36.52%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	1.6758 of 5 stars	$22.64 -11.3%	$25.00 +10.4%	+1,722.1%	$3.26B	$62.38M	N/A	90	Earnings Report Analyst Upgrade Gap Down
AXSM Axsome Therapeutics	2.3605 of 5 stars	$224.21 +0.2%	$251.89 +12.3%	+122.7%	$11.52B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.9073 of 5 stars	$22.96 +2.0%	$27.90 +21.5%	+67.2%	$11.41B	$4.72B	N/A	9,400	Analyst Downgrade
RDY Dr. Reddy's Laboratories	3.3076 of 5 stars	$13.33 -0.2%	$16.90 +26.8%	-7.9%	$11.12B	$3.81B	17.31	27,811	News Coverage Earnings Report Analyst Downgrade Gap Up
ARWR Arrowhead Pharmaceuticals	2.2158 of 5 stars	$73.84 -3.3%	$84.20 +14.0%	+409.7%	$10.33B	$829.45M	48.23	400	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. AXSM, ELAN, RDY, ARWR, and ABVX

How does Tango Therapeutics compare to Axsome Therapeutics?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Summary

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Tango Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. AXSM, ELAN, RDY, ARWR, and ABVX

How does Tango Therapeutics compare to Axsome Therapeutics?

Is AXSM or TNGX more profitable?

Which has more volatility and risk, AXSM or TNGX?

Do institutionals and insiders have more ownership in AXSM or TNGX?

Do analysts recommend AXSM or TNGX?

Which has preferable valuation and earnings, AXSM or TNGX?

Does the media prefer AXSM or TNGX?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Which has stronger earnings and valuation, TNGX or ELAN?

Which has more risk and volatility, TNGX or ELAN?

Do analysts rate TNGX or ELAN?

Do institutionals & insiders have more ownership in TNGX or ELAN?

Does the media refer more to TNGX or ELAN?

Is TNGX or ELAN more profitable?

Summary

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Is TNGX or RDY more profitable?

Which has more risk and volatility, TNGX or RDY?

Which has stronger earnings and valuation, TNGX or RDY?

Do analysts rate TNGX or RDY?

Does the media refer more to TNGX or RDY?

Do institutionals & insiders have more ownership in TNGX or RDY?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Is TNGX or ARWR more profitable?

Which has more volatility & risk, TNGX or ARWR?

Which has higher earnings & valuation, TNGX or ARWR?

Do analysts rate TNGX or ARWR?

Does the media refer more to TNGX or ARWR?

Do insiders and institutionals have more ownership in TNGX or ARWR?

Summary

How does Tango Therapeutics compare to Abivax?

Does the media refer more to TNGX or ABVX?

Which has more volatility & risk, TNGX or ABVX?

Is TNGX or ABVX more profitable?

Which has higher earnings & valuation, TNGX or ABVX?

Do insiders and institutionals have more ownership in TNGX or ABVX?

Do analysts rate TNGX or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools